Bavarian eases up on categorical statements on Covid-19 vaccine financing
Up until now, Bavarian Nordic's management has been adamant that it would only take the clinical development of the company's Covid-19 vaccine further if money came in from outside, but CEO Paul Chaplin might be starting to change his tune.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
The Covid-19 situation has changed significantly since Bavarian Nordic made a deal with Adaptvac for the latter's coronavirus vaccine just under a year ago.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
